NERV earnings analysis
What we found in NERV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Minerva Neurosciences reported a significant net loss of $125.4 million for Q1 2026, driven by rising R&D and G&A expenses. This marks a stark increase from a loss of $3.8 million in the same quarter of the previous year, reflecting challenges in advancing their drug candidate, roluperidone, following a setback with a regulatory submission.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Dramatic EPS Decline
- The diluted EPS plunged to -$2.86 for Q1 2026, a sharp drop from -$0.50 in Q1 2025.
- R&D Expenses Surge
- Research and development expenses rose to $5.3 million in Q1 2026 from $1.4 million in Q1 2025, a $3.9 million increase.
- Massive Non-Cash Charge
- A non-cash expense of $109.4 million related to the change in fair value of warrant liabilities was recognized in this quarter.
- Cash Position Maintained
- Cash and marketable securities at the end of Q1 2026 totaled approximately $78.2 million, adequate for the next 12 months.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Total Liabilities
- Total GAAP liabilities increased to $343.1 million as of March 31, 2026, up from $233.8 million at the end of 2025.
- Increased Cash Burn Risks
- Net cash used in operating activities was approximately $5.4 million for Q1 2026, up from $4.1 million in the same period last year.
- Regulatory Approval Uncertainty
- The company faces significant risks as they attempt to resubmit the NDA for roluperidone following a Complete Response Letter from the FDA in February 2024.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.86
What they said about what is next.
Management expects to continue incurring significant losses as they advance clinical trials.
The filing reads worse than the one before it.
What came before.
- 10-K · March 11, 2026
- Minerva (NERV) is a clinical-stage CNS-focused biotech advancing roluperidone through a planned Phase 3 confirmatory trial (C19) to address an FDA Complete Response Letter; the company recorded a net loss of $293.4…
- 10-Q · May 13, 2025
- Minerva reported a narrowed net loss of $3,752,972 (loss per share $0.50) in Q1 2025 versus a net loss of $8,568,805 (loss per share $1.13) in Q1 2024. Total expenses fell to $3,902,884 from $6,681,963, driven primarily…
- 10-K · February 25, 2025
- Minerva is a clinical-stage CNS-focused biopharma advancing roluperidone (MIN-101) for negative symptoms of schizophrenia and MIN-301 for Parkinson’s disease, with strategy centered on acquiring differentiated CNS…
- 10-Q · August 6, 2024
- Minerva reported no revenue and a net loss of $8,233,487 for the three months ended June 30, 2024 (basic and diluted loss per share $1.09). R&D spending rose materially year-over-year while cash declined to $30.981…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NERV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever